Ardelyx is a company dedicated to improving the lives of patients by discovering, developing and commercializing first-class targeted therapies that can improve patient care. Their research expertise in biological mechanisms and pathways allows them to develop a series of drugs to meet important clinical needs, including better management of complications related to kidney and cardiovascular diseases, with the goal of improving this service to an underserved patient population. Their main drug, tenapanor, is a first-class, targeted small molecule drug currently under review by the FDA for controlling serum phosphorus in adult patients with chronic kidney disease after dialysis. They are also developing early-stage drugs that will further utilize their discovery capabilities and deep understanding of transport mechanisms, and target specific pharmacological pathways. Ardelyx further offers diverse employee benefits such as disability insurance, flexible work plans , a retirement savings plan, including employer contributions and the opportunity for their own tax-advantaged savings, flexible spending benefit plans for medical and dependent care, among others.
Similar companies
